Ozanezumab

N/A

Report date: 2024/06/27 20:00:09

Base Information

Drug NameOzanezumab
Drug Alias Name奥扎奈珠单抗ozanezumabum奥扎组单抗1223249GSK-1223249
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReticulon-4 inhibitors
TargetsReticulon-4
Therapy Area/IndicationsAmyotrophic Lateral SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsAmyotrophic Lateral SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG